Search

Displaying results 2321 - 2330 of 10000 in total
  1. Drug

    Zinc ascorbate

    go.drugbank.com/drugs/DB14485
    ApprovedNutraceutical

    Mixtures: Enl
  2. Drug

    Anisotropine methylbromide

    go.drugbank.com/drugs/DB00517
    Approved

    action on the bile ducts and gallbladder. … Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.

  3. Drug

    Apomorphine

    go.drugbank.com/drugs/DB00714
    ApprovedInvestigational

    It was first synthesized in 1845 and first used in Parkinson's disease in 1884. … [A203597,A203618] Apomorphine was granted FDA approval on 20 April 2004.[L13919]

    Categories: Drugs Used in Erectile DysfunctionProducts: DACEPTON® 30MG/3 ML SOLUCION INYECTABLE, APO-GO PEN 10 MG/ML
  4. Drug

    Bifidobacterium longum infantis

    go.drugbank.com/drugs/DB14222
    ApprovedInvestigationalWithdrawn

    Mixtures: BİOBER-ZN ORAL SÜSPANSİYON İÇEREN FLAKON, 5 ADET
  5. Drug

    Rosin

    go.drugbank.com/drugs/DB11165
    Approved

    In the pharmaceuticals, rosin is used in film forming and coating tablets and enterically administered agents, as well as forming microcapsules and nanoparticles. … Rosin has shown to mediate antibacterial actions on Gram-positive bacterial species [A27267].

    Categories: Compounds used in a research, industrial, or household setting, Complex Mixtures
  6. Drug

    Bordetella pertussis toxoid antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14388
    ApprovedInvestigational

    Bordetella pertussis toxoid antigen (formaldehyde inactivated) is a vaccine.

    Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Repevax Injektionssuspension in einer Fertigspritze
  7. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … [L23554] Lumasiran was granted FDA approval on 23 November 2020.[L23394]

  8. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators.

  9. Drug

    Tegafur

    go.drugbank.com/drugs/DB09256
    ApprovedInvestigational

    It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with [DB09257] and [DB03209], or along with [DB00544] as [DB09327]. … When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the

    International brands: ESUEEW AN T
  10. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular